News 
Market Data 
Discover
stockguard
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
| Ticker | Board | News | Price | Change | Chg% | Added | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| BILL | Bill.com Holdings Inc | 61.415 | 0.155 | 0.25% | 01/06/2020 | |||||
|
My BILL Pitch: Bill.com Holdings, Inc. provides cloud-based software that digitizes and automates back-office financial operations for small and midsize businesses worldwide. It offers artificial-intelligence (AI)-enabled financial software platform. The company provides software-as-a-service, cloud-based payments
|
||||||||||
| MRVL | Marvell Technology Inc | 64.04 | 0.18 | 0.28% | 01/01/2020 | |||||
|
My MRVL Pitch: Now is the time to get in on a play that has a great 5G outlook plus it pays a divy to wait.
|
||||||||||
| IOTS | Adesto Technologies | 01/01/2020 | ||||||||
|
My IOTS Pitch: Inexpensive internet of things IoT`s play at a low entry price.
|
||||||||||
| MYOV | Myovant Sciences Ltd | 26.98 | 0.0 | 0.00% | 11/02/2019 | |||||
|
My MYOV Pitch: $MYOV near term catalysts 3 Phase trials. This quarter they will release top line data from the only ph 3 they need to validate Relugolix for prostate cancer treatment.
|
||||||||||
| ABBV | Abbvie Inc | 168.375 | -1.165 | -0.69% | 11/02/2019 | |||||
|
My ABBV Pitch: Just an overall great company with a high dividend.
|
||||||||||
| LABU | Direxion S&P Biotech Bull 3X ETF | 89.72 | -2.26 | -2.46% | 07/04/2017 | |||||
|
My LABU Pitch: To play the ongoing upswing in the biotech industry and to the ageing population that will need these new discoveries along with newer drugs as they get approved.
|
||||||||||
| TGTX | TG Therapeutics Inc | 13.98 | -0.27 | -1.89% | 07/04/2017 | |||||
|
My TGTX Pitch: Low stock entry price with a number of positive late stage ongoing trials for different indications for unmet diseases.
|
||||||||||
